# Haleon account plan

> Haleon is a consumer health company behind Sensodyne, Centrum, Advil and Panadol, with £11,030m of 2025 revenue and about 24,000 employees.

## At a glance

Haleon is a consumer health company, spun off from GSK in 2022 and listed in London with American Depositary Shares in New York. It sells oral health, vitamins and supplements, pain relief, respiratory, digestive and skin health products under brands such as Sensodyne, parodontax, Centrum, Advil, Panadol, Voltaren and Otrivin, reaching 1.4bn consumers in a market it sizes at c.£200bn. FY2025 revenue was £11,030m (organic +3.0%), adjusted operating profit £2,526m (22.9% margin) and free cash flow £1,913m, with an average workforce of about 24,000. In 2025, EMEA & LatAm brought £4,592m of revenue, North America £3,866m and APAC £2,572m; from 2026 it reports North America, Europe, APAC and International. Brian McNamara is CEO.

## Business units

- **Oral Health** (about 31% of FY2025 revenue (£3,461m)): Sensodyne (global #1 in sensitivity toothpaste), parodontax and Corega/Polident/Poligrip denture care, focused on premium therapeutic oral care. It is the growth engine: +7.9% organic in 2025 and +8.8% to £930m in Q3 2026, with Sensodyne growing at three times the US market.
- **Pain Relief** (about 23% of FY2025 revenue (£2,564m)): Voltaren, Panadol, Advil, Excedrin, Fenbid and Grand-Pa. Organic growth was +2.3% in 2025 and +0.5% in Q3 2026; Voltaren 2% is in over 100k stores across 75 cities in China and Advil Liquid gained FDA approval.
- **Respiratory Health** (about 17% of FY2025 revenue (£1,873m)): Otrivin, Theraflu, Flonase, Robitussin and Smokers' Health. Revenue fell 11.7% reported in 2025, including the non-US Smokers' Health divestment, and again 2.0% in Q3 2026 on a weak cold and flu season.
- **Vitamins, Minerals & Supplements (VMS)** (about 15% of FY2025 revenue (£1,685m)): Haleon is #1 in VMS globally with Centrum, Caltrate and Emergen-C. Organic growth was +1.9% in 2025; in Q3 2026 VMS fell 0.5% as Centrum declined in Europe and OTC Centrum imports into China were suspended.
- **Digestive Health** (about 9% of FY2025 revenue (£987m)): Tums, ENO and Benefiber, with the US, India and Brazil c.85% of sales. Benefiber grows double digit on GLP-1 activations while Nexium declines.
- **Therapeutic Skin Health & Other** (about 4% of FY2025 revenue (£460m)): Zovirax/Abreva for cold sores, Bactroban for wound healing, Fenistil, and Eroxon in Other. Organic growth was +2.0% in 2025.

## Strategic priorities

- **Win as One: 1bn more consumers by 2030**: The strategy launched in May 2025 aims to reach 1bn more consumers by 2030 and deliver industry-leading shareholder returns, through innovation-led premiumisation and reaching lower-income consumers, such as Rs. 20 Sensodyne packs in more than 500,000 Indian stores.
- **Return to stronger volume growth**: After Q3 2026 growth below expectations, the CEO's key priority is "to drive stronger volume growth" and get back to the medium-term guidance of 4-6% organic revenue growth.
- **Four commercial priorities for 2027**: Scale innovation (38 new Centrum claims unlocked with AI tools), an AI-enhanced perfect store model in 20 markets by Q1 2027, revenue growth management analytics in 16 of the top 20 markets, and more effective A&P spending.
- **Supply chain productivity**: £800m gross supply chain savings by 2030 and 50-80bps a year of gross margin expansion; SKUs were cut c.27% and formulations c.26% since the start of 2024, with over 180 robots added in 18 months.
- **New operating model**: Announced in January 2026: a Chief Growth Officer over categories, marketing and a new Commercial Excellence team, and consolidation from three regions and 14 business units to six operating units, with c.£175m-200m of annualised gross savings over two years.

## Latest results

In Q3 2026 (three months to 30 September), revenue was £2,868m, up 2.6% organically (price +2.1%, volume/mix +0.5%), which management said was below expectations. Oral Health grew 8.8% and International 6.9%, while Respiratory Health fell 2.0% and Europe 0.6%. In H1 2026, revenue was £5,602m (organic +2.6%) and adjusted operating profit £1,364m, up 8.2% at constant currency, with a 24.3% margin. Haleon cut its FY2026 organic revenue growth guidance to around 2.5% from 3-5%, citing the suspension of Centrum OTC imports into China (c.£75m of FY2025 revenue) and a Brazil go-to-market change, but kept high single-digit adjusted operating profit growth.

## Investments and deals

- **Oral health manufacturing in India and China**: c.£175m for a new oral health plant in India, opening 2028, and c.£65m for an oral health plant in China.
- **Microsoft partnership**: A five-year strategic partnership with Microsoft announced with the H1 2026 results, alongside AI tools for claims, perfect store and pricing analytics.
- **Share buybacks**: £1.1bn was returned to shareholders in 2025; a further £500m buyback announced in Q3 2026 brings 2026 shareholder returns to £1.6bn.
- **R&D facility and China joint venture**: c.£200m is being invested in a new R&D facility, and Haleon bought the remaining 12% of its TSKF joint venture in China; bolt-on acquisitions remain the M&A focus.

## Challenges and risks

- **Weak cold and flu season**: US cough, cold and flu category consumption fell 8% in Q3 2026, and Respiratory Health declined in 2025 and 2026.
- **Centrum disruption in China**: A raw material classification change forced Haleon to stop importing for OTC-registered Centrum products in China, a 50bps drag on Q3 group growth expected to last through Q4 and 2027.
- **Weak consumer demand**: The CEO says US consumers are "quite reticent" amid tariffs and the war in Iran, and Europe faces a weak, value-seeking consumer, with Q3 2026 volume/mix down 2.7% there.
- **Execution of the operating model change**: Restructuring costs for the new operating model cut H1 2026 reported operating profit by 2.6%, and the risk factors note no assurance the model will deliver the expected benefits.
- **Geopolitical and ingredient risks**: Principal risks include the US-China relationship between its two largest markets, tariffs, trusted ingredients and supply chain resilience.

## What leadership says

> "we're not satisfied with the broader group growth rate and the consistency of our performance in recent quarters." — Brian McNamara, Chief Executive Officer, Q3 2026 results call, 29 October 2026

> "the last phase for me is to create a truly agile, performance-focused, consumer-centric company." — Brian McNamara, Chief Executive Officer, Semafor, The CEO Signal, 25 September 2026

> "on the premium side, there's tremendous opportunity. On the low-income side, there's tremendous opportunity. In the middle, there's quite a bit of stress and pressure on the consumer." — Brian McNamara, Chief Executive Officer, Semafor, The CEO Signal, 25 September 2026

> "for the first time since separation, we are now in line with our leverage target of around 2.5 times from a starting point of four times." — Dawn Allen, Chief Financial Officer, Q3 2026 results call, 29 October 2026


## Where a supplier can help

- **Retail execution and AI tooling**: The AI-enhanced perfect store model rolling out to 20 markets and revenue growth management analytics in 16 of the top 20 markets create needs for retail execution, pricing and promotion analytics tools.
- **Marketing effectiveness and digital commerce**: Haleon is shifting A&P toward precise audiences, social content, creators and digital commerce (20% of US revenue), so media, retail media and creator-marketing partners fit the A&P effectiveness priority.
- **Supply chain automation and savings**: The £800m supply chain savings target, SKU simplification and new plants in India and China call for automation, robotics and manufacturing suppliers.
- **Operating model transformation**: Moving from 14 business units to six operating units, with a new Commercial Excellence team, opens doors for consulting, change management and commercial systems support.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report and Form 20-F 2025](https://www.sec.gov/Archives/edgar/data/1900304/000110465926027443/hln-20251231x20f.htm)

Annual report · 2026-03-13

- Haleon is "A world-class consumer company focused on better everyday health", listed in London and New York (ADS); it reports six categories (Oral Health, VMS, Pain Relief, Respiratory Health, Digestive Health, Therapeutic Skin Health & Other) in a c.£200bn market, with brands such as Sensodyne, parodontax, Centrum, Advil, Panadol, Voltaren and Otrivin.
- FY2025: revenue £11,030m (reported -1.8%, organic +3.0%, below medium-term expectations because of a weak cold and flu season and low consumer confidence in North America); adjusted operating profit £2,526m (+10.5% organic), adjusted operating margin 22.9%, free cash flow £1.9bn, diluted EPS 18.5p.
- Oral Health is the growth engine: £3,461m revenue, +7.9% organic; Respiratory Health fell to £1,873m (-1.9% organic, -11.7% reported after the non-US Smokers' Health divestment).
- Geography (2025 revenue): EMEA & LatAm £4,592m (+4.7% organic), North America £3,866m (-0.4%), APAC £2,572m (+5.2%); average workforce about 24,000.
- "Win as One" strategy (launched May 2025): reach 1bn more consumers by 2030 and deliver industry-leading shareholder returns, via four drivers (Health in more hands, Superior brands, Wired for excellence, Full potential people).
- Medium-term guidance: 4-6% annual organic revenue growth, high single-digit adjusted operating profit growth at constant currency; 2026 guidance 3-5% organic growth.
- Productivity: £800m gross supply chain savings targeted over five years; adjusted gross margin up 200bps to 65.2%; A&P at 20.5% of revenue.
- January 2026 operating model: a new Chief Growth Officer (Filippo Lanzi), a Chief Transformation Officer (Björn Timelin), and consolidation from three regions and 14 business units to six operating units; new Chair Vindi Banga from 1 January 2026.
- Capital: £1.1bn returned in 2025 (incl. £500m buyback), net debt £7,263m at 2.6x net debt/adjusted EBITDA (target c.2.5x), full ownership of the China TSKF joint venture, £500m buyback allocated for 2026.
- Principal risks: growth model, people and organisation, trusted ingredients, supply chain resilience, ESG, cyber security, geopolitical instability (including US-China relations, its two largest markets).

### [2026 Half Year Results (six months ended 30 June 2026)](https://www.sec.gov/Archives/edgar/data/1900304/000165495426007001/a1bi_h12026releasev31.pdf)

Interim report · 2026-07-30

- H1 2026 (six months to 30 June): revenue £5,602m, organic growth +2.6% (price 2.1%, volume/mix 0.5%), reported +2.2%; Q2 organic +3.1% after a weaker Q1.
- Adjusted operating profit £1,364m, +8.2% at constant currency; adjusted operating margin 24.3%; adjusted gross margin 66.5% (+140bps CER); adjusted diluted EPS 10.3p (+12.0%).
- Reported operating profit fell 2.6% to £1,172m, hit by restructuring costs of the new operating model.
- Oral Health (33% of revenue) grew 7.3%; Respiratory Health (15%) fell 4.7% on a weak cold and flu season, notably in China.
- New reporting segments: North America £1,830m (+2.0%), Europe £1,631m (+0.6%), APAC £1,182m (+3.3%), International (LatAm, MEA, India Subcontinent) £959m (+6.3%).
- New operating model (CGO role, six Operating Units) moves to implementation: annualised gross savings of c.£175m-200m over two years.
- Investments: c.£175m oral health plant in India and c.£65m oral health plant in China; five-year strategic partnership with Microsoft.
- Free cash flow £769m; net debt £7.5bn at 2.5x; £457m of the £500m 2026 buyback done; interim dividend 2.4p (+9%).
- FY2026 guidance unchanged at the time: organic revenue growth 3-5%, high single-digit adjusted operating profit growth; medium-term 4-6%.

### [2026 Q3 Trading Statement](https://www.sec.gov/Archives/edgar/data/0001900304/000165495426009194/q32026pressreleasevf.pdf)

Interim report · 2026-10-29

- Q3 2026 (three months to 30 September): revenue £2,868m, organic +2.6% (price +2.1%, volume/mix +0.5%), reported +2.5%; below management's expectations.
- Oral Health grew 8.8% to £930m; Respiratory Health fell 2.0% on soft cold and flu consumption and lower North American orders; VMS -0.5%.
- Segments: North America £992m (+2.5%), Europe £798m (-0.6%), APAC £593m (+3.9%), International £485m (+6.9%, India Subcontinent high-teens); emerging markets +5.1%.
- China: a raw material classification change forced Haleon to stop importing for Centrum OTC-registered products (c.£75m revenue in FY2025); not a quality or safety issue.
- Brazil go-to-market change accelerated into Q4 2026, a c.£15-20m hit to Q4 net revenue.
- FY2026 guidance cut to around 2.5% organic revenue growth (from 3-5%); high single-digit adjusted operating profit growth maintained.
- A further £500m allocated to share buybacks.
- CEO Brian McNamara: the key priority is "to drive stronger volume growth" and return to consistent delivery of medium-term guidance.

### [How splitting from GSK taught Haleon a spin-off is not a finish line (Semafor, The CEO Signal)](https://www.semafor.com/article/09/25/2026/how-splitting-from-gsk-taught-haleon-a-spin-off-is-not-a-finish-line)

Executive talk · Brian McNamara, Chief Executive Officer · 2026-09-25

- Interview of CEO Brian McNamara by Semafor's Andrew Edgecliffe-Johnson (The CEO Signal), September 2026, four years after the 2022 spin-off from GSK.
- He describes three phases: separate and deal with leverage; set the new strategy (a billion more consumers, industry-leading shareholder returns); now "create a truly agile, performance-focused, consumer-centric company".
- He found "the organization was quite tired" after the Novartis and Pfizer integrations and the separation, and changed 13 of his 15-member leadership team, hiring from P&G, Estée Lauder, Unilever and L'Oréal.
- Only maybe 20% of his former divisional role carried over to being a listed-company CEO: educating a new board, debt, capital allocation, an external role on technology and geopolitics.
- Strategy of innovation-led premiumisation plus reach to low-income consumers fits a K-shaped economy: opportunity at both ends, "stress and pressure" in the middle, in the US, Europe and globally.
- US consumers are reticent amid tariffs and the war in Iran; some no longer buy cold and flu products ahead of need, which has taken growth off the US categories.
- A US listing is "not on our agenda right now".

### [Haleon Q3 2026 results call, prepared remarks](https://www.earningswhispers.com/transcript/HLN/Q32026)

Executive talk · Brian McNamara, Chief Executive Officer; Dawn Allen, Chief Financial Officer · 2026-10-29

- Prepared remarks of the Q3 2026 results call (29 October 2026) by CEO Brian McNamara and CFO Dawn Allen, introduced by Head of IR Jo Russell.
- Q3 organic growth of 2.6% "was below our expectations"; FY2026 now around 2.5%, with high single-digit operating profit growth maintained thanks to productivity.
- Bright spots: Oral Health high single digit (+8.8%), Sensodyne consumption three times the US market, Centrum US consumption up double digit over 12 weeks, India high teens, Douyin sales up nearly 100% year to date.
- Headwinds: US cold and flu category consumption down 8% in Q3; Centrum OTC import suspension in China (50bps drag on group growth in the quarter, impact expected through Q4 and 2027); Brazil go-to-market change (£15-20m in Q4).
- Four priorities for Q4 and 2027: scale innovation (Advil liquid FDA approval, 38 new Centrum claims unlocked with AI tools), consistent commercial execution (AI-enhanced perfect store in 20 markets by Q1 2027), revenue growth management (16 of top 20 markets by Q1), more effective A&P.
- Digital commerce is 20% of US revenue; 14 clinical trials run this year.
- CFO: leverage back at the c.2.5x target from four times at separation; further £500m buyback brings 2026 shareholder returns to £1.6bn; working capital down 19 days over two years.

## Questions about Haleon

### What does Haleon do?

Haleon makes consumer health products in oral health, vitamins and supplements, pain relief, respiratory, digestive and skin health, under brands including Sensodyne, Centrum, Advil, Panadol, Voltaren and Otrivin.

### What is Haleon's revenue?

FY2025 revenue was £11,030m with adjusted operating profit of £2,526m. H1 2026 revenue was £5,602m, and FY2026 organic growth is now guided at around 2.5%.

### How many employees does Haleon have?

Haleon had an average workforce of about 24,000 in 2025.

### Who leads Haleon?

Brian McNamara is CEO, Dawn Allen is CFO and Vindi Banga has been Chair since 1 January 2026.

### What is Haleon's strategy?

Its Win as One strategy aims to reach 1bn more consumers by 2030 and deliver industry-leading shareholder returns through premium innovation, reach to lower-income consumers, supply chain productivity and a new six-unit operating model.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
